Literature DB >> 2820346

Cryptosporidial and cytomegaloviral hepatitis and cholecystitis.

D G Kahn, J M Garfinkle, D C Klonoff, L J Pembrook, D J Morrow.   

Abstract

We describe an immunosuppressed patient with enteric cryptosporidiosis who developed combined cryptosporidial and cytomegaloviral hepatitis and cholecystitis as well as Enterobacter cloacae cholecystitis. To our knowledge, the presence of Cryptosporidium in a liver biopsy specimen has not previously been reported.

Entities:  

Mesh：

Year:  1987        PMID： 2820346

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN： 0003-9985            Impact factor:   5.534


  6 in total

1.  Histopathological method for diagnosis of cryptosporidiosis using monoclonal antibodies.

Authors:  A Bonnin; T Petrella; J F Dubremetz; J F Michiels; D Puygauthier-Toubas; P Camerlynck
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-09       Impact factor: 3.267

2.  New mouse models for chronic Cryptosporidium infection in immunodeficient hosts.

Authors:  B L Ungar; J A Burris; C A Quinn; F D Finkelman
Journal:  Infect Immun       Date:  1990-04       Impact factor: 3.441

3.  AIDS-related cholangiopathy. Critical analysis of a prospective series of 26 patients.

Authors:  Y Benhamou; E Caumes; Y Gerosa; J F Cadranel; E Dohin; C Katlama; P Amouyal; J M Canard; N Azar; C Hoang
Journal:  Dig Dis Sci       Date:  1993-06       Impact factor: 3.199

4.  Prevalence of cryptosporidiosis in HIV-infected patients with diarrhoeal illness.

Authors:  O Brandonisio; P Maggi; M A Panaro; L A Bramante; A Di Coste; G Angarano
Journal:  Eur J Epidemiol       Date:  1993-03       Impact factor: 8.082

5.  Infection dynamics and clinical features of cryptosporidiosis in SCID mice.

Authors:  J R Mead; N Ilksoy; X You; Y Belenkaya; M J Arrowood; M T Fallon; R F Schinazi
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

Review 6.  Cryptosporidiosis.

Authors:  W L Current; L S Garcia
Journal:  Clin Microbiol Rev       Date:  1991-07       Impact factor: 26.132
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.